ACOG’s menopause update reviews modest self-reported sleep gains with hormone therapy and guidance focused on vasomotor-related sleep disruption.
On October 15, 2026, the American College of Obstetricians and Gynecologists (ACOG) published Clinical Practice Guideline No. 13 online in Obstetrics & Gynecology. According to Contemporary OB/GYN’s account, the guideline addresses menopause-related vasomotor symptoms alongside sleep disturbance and mood symptoms through hormonal, nonhormonal and nonpharmacologic care.
The central sleep finding comes from a meta-analysis of 15 randomized controlled trials involving 27,715 participants. Contemporary OB/GYN reports that menopausal hormone therapy (MHT) was associated with a small improvement in self-reported sleep quality. The analysis did not find improvement in objective polysomnography measures.
Self-reported sleep quality describes how participants rated their own sleep. Polysomnography provides an objective sleep assessment. These are different outcomes, so a change in one should not be presented as a change in the other.
The reported standardized mean difference was −0.13, with a 95% confidence interval of −0.18 to −0.08. That statistic describes a small difference across the pooled studies. It is not a count of extra minutes asleep or a prediction of how much better an individual will feel.
Contemporary OB/GYN also reports that transdermal and 17β-estradiol regimens showed the largest effects on self-reported sleep quality. That finding does not establish a universally best formulation for sleep. Choosing a regimen remains a clinical decision based on the person’s circumstances.
The other boundary concerns the symptom being treated. ACOG’s hormone-therapy recommendation addresses vasomotor-related sleep disturbance, meaning disruption connected with hot flashes or night sweats. It is not a blanket recommendation for every kind of insomnia or poor sleep.
ACOG strongly recommends systemic MHT for vasomotor-related sleep disturbance in people without contraindications. The recommendation carries a moderate-quality evidence rating. Its clinical focus is the connection between menopause symptoms and disrupted sleep rather than a sleep complaint considered in isolation.
The guideline also distinguishes between treatment regimens. It describes estrogen plus a progestogen for those with a uterus, or estrogen alone when endometrial protection is not needed. These distinctions belong in a discussion with a qualified clinician rather than a self-directed choice based on the sleep finding.
For VMS or vasomotor-related sleep disturbance, ACOG recommends considering MHT initiation before age 60 or within 10 years of the start of natural menopause. This applies to people without contraindications and carries a low-to-moderate-quality evidence rating. Age and timing sit within the assessment rather than replacing a review of medical history and risks.
ACOG calls for shared decision-making that includes symptoms and treatment priorities. The discussion also covers medical history and baseline risks involving cardiovascular disease, breast cancer and venous thromboembolism. The patient’s goals are part of that decision rather than an afterthought.
This broader menopause-symptom remit is also reflected in Healio’s coverage of the expanded guidance. The new guideline replaces ACOG’s January 2014 Practice Bulletin No. 141 and brings sleep disturbance into the same clinical framework as vasomotor and mood symptoms.
Hormone therapy is one part of the guideline’s treatment framework. For people who do not want it or have a contraindication, ACOG recommends neurokinin receptor antagonists for VMS and vasomotor-related sleep disturbance. Which option fits an individual remains a discussion for qualified care.
ACOG also conditionally suggests cognitive behavioral therapy (CBT), mindfulness-based interventions and exercise for menopause-related sleep disturbance. These options give the clinical conversation more than one direction. Their inclusion does not mean everyone needs to adopt all of them or build a demanding new recovery routine.
The distinction between a strong and a conditional recommendation matters here. Contemporary OB/GYN reports that the guideline used a modified GRADE framework, with recommendation strength and evidence quality rated separately. A strong recommendation reflects a judgment that benefits outweigh harms for most patients in the specified group.
A conditional recommendation depends more on individual circumstances and preferences. That makes it useful to ask why an option fits the symptoms being discussed. Simply appearing in the same guideline does not give every approach the same role or recommendation strength.
For someone in midlife dealing with disrupted sleep alongside menopause symptoms, the most direct everyday adjustment is to notice whether those symptoms occur together. A brief note about the night can help organize a later clinical conversation. This is preparation for shared decision-making, not a test that identifies the cause of poor sleep.
The useful information is straightforward:
No elaborate scoring system is needed to put those observations into words. The purpose is to describe the pattern clearly enough to discuss whether it fits the symptom connection addressed by the guideline. A clinician can then place that account alongside health history and treatment preferences.
This is a narrower task than trying to fix every possible influence on sleep at once. The finding does not require turning bedtime into a project involving new products or multiple simultaneous routine changes. Its practical value is in making a specific symptom pattern easier to discuss.
Relaxopia’s guide to sleep across the menopause transition provides background for readers preparing that conversation. The immediate aim is not to select a treatment independently. It is to arrive with a clearer description of what is happening and what help would be useful.
Shared decision-making becomes more concrete when the conversation starts with the problem rather than a preferred treatment. The guideline supports discussing symptom connections and personal priorities together. The following questions keep that discussion close to the evidence.
“Could my sleep disruption be related to hot flashes or night sweats?” is a useful opening question. It names the connection addressed by ACOG without assuming that the connection has already been established. It also gives the clinician a clear starting point for reviewing the symptom history.
If sleep difficulties are persistent or complex, the discussion can extend beyond this menopause guideline. Describing the full problem helps keep the appointment focused on the person’s experience rather than on fitting every complaint into one explanation.
“What benefits and risks matter most in my situation?” brings the guideline’s shared-decision approach into practical terms. Relevant discussion includes age and time since natural menopause. It also includes medical history and the baseline risks ACOG identifies.
Preferences deserve equal clarity. Someone may want to discuss hormone therapy or may prefer to hear about nonhormonal options. Stating that preference gives the clinician useful information while leaving room to explain how the available choices relate to the symptoms.
“What change are we hoping this option will address?” helps connect a treatment discussion with a meaningful goal. The answer might center on vasomotor symptoms or on the sleep disturbance associated with them. Naming the goal gives the conversation a clearer focus than asking for better sleep in the abstract.
A related question is how that goal will be reviewed over time. The guideline’s emphasis on patient priorities makes the person’s account part of the decision. Agreeing on what matters also creates a clear subject for follow-up discussions with the clinician.
“Which nonhormonal or behavioral options are relevant to my symptoms?” opens the rest of the guideline’s framework. A clinician can explain where medication options or the conditionally suggested behavioral approaches fit. The discussion can also address which choices match the person’s preferences and circumstances.
For readers organizing a broader account of disrupted rest, Relaxopia’s framework for reviewing sleep problems offers another starting point. The aim is a manageable conversation about the pattern and possible next steps, not a long list of tasks to complete before seeking help.
The update creates a clearer place for sleep within menopause care. Its practical contribution is a more specific conversation: which symptoms occur together and which options fit the person experiencing them. That approach keeps clinical recommendations connected with everyday experience.
Long-term follow-up can also keep the person’s priorities visible as symptoms and circumstances change. Rather than treating one treatment decision as the whole recovery plan, future discussions can return to the goals that first brought sleep into the appointment.
As this guidance enters routine care, will closer attention to symptom patterns and patients’ own experience of rest lead to more useful long-term approaches to midlife recovery?
Treating hormone therapy as a general answer to poor sleep blurs the guidance, so Relaxopia separates symptom-specific findings from broad recovery advice. Its research-led coverage helps adults 35+ sort conflicting advice about exercise and routines while keeping sleep connected with stress, fatigue and everyday recovery.
Stay connected for research-led guidance on sleep quality, stress, circadian rhythm, recovery, fatigue and everyday energy. Clear ideas for adults 35+ who want to sleep better, recover more fully and feel more capable through the day.
Explore practical guidance on sleep, stress and recovery without chasing every new hack, device or promise.
explore the blog